DXS

Crown CRO is a privately owned Finnish CRO founded in 2005. Our headquarters are in Espoo, which is located in Finland’s capital city region. Crown CRO offices are located in Finland, Sweden, Denmark, Norway, Estonia, Latvia and Lithuania. We have ongoing trials managed by our employees in Netherlands, Belgium, UK, Iceland, Ukraine and Belarus. Rest of the Europe and USA we cover through our qualified CRO network.

Our services cover Phase I – IV clinical development from protocol design to final reporting or any parts of the trial in various business models. Data services, Regulatory consulting, Pharmacovigilance, QA, Study Rescue Services and Medical Translation services complete the service package.

Our key therapeutic areas include, but not limited to, CNS, Oncology, Endocrinology, Cardiovascular, Respiratory and Musculoskeletal. We also have strong recent experience in Medical Devices from various indications.

Our passion for research across all our in-house Full-Service functions provide effective and innovative solutions with seamless cooperation for Phase I-III trials in Europe offering special focus on Nordic-Baltic area, together with our own Global Data Services ensuring consistency regardless of where your trials are located, offer you unrivalled customer attention, flexibility and high local level expertise which are key assets you can count on.

See www.crowncro.com for more information.

EPHORAN Multi-Imaging Solutions is a Contract Research Organization providing imaging expertise and knowledge to study, develop and promote the application of imaging technologies in preclinical drug research and development.

EPHORAN provides the opportunity to apply a translational pharmacological approach in drug R&D, evaluating in animal models a molecular-based proof of biological activity and mechanism of action, and translating it into the clinical setting. All the Techniques extensively employed in the clinical setting(e.g. PET, CT, SPECT, MRI, US and in Optical Imaging, both visible light and Near Infra Red) are available.

EPHORAN fosters the development of diagnostic tools, reagents and methodologies for experimental imaging and makes the drug development faster and more cost effective. Pharmaceutical companies will take advantage from its preclinical imaging technologies to carry on more effectively their R&D projects in different therapeutic such as oncology, cardiovascular and CNS. The application of Imaging techniques allows a significant reduction of the time-to-market of novel compounds. Other users that will benefit from access to Ephoran’s services are Researchers from academic and research institution.

Founded in 1997, Ergomed plc is a global provider of high-quality services to the biopharmaceutical industry, spanning all phases of clinical trials, post-approval pharmacovigilance, and medical information. Ergomed’s fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, and Ergomed Clinical Research, a complete, global Phase I-IV clinical development and trial management services with a strong heritage in the development of drugs in rare diseases and oncology.

• 1 300+ highly qualified professionals
• Global full-service CRO
• 24+ years of experience
• Therapeutic specialization in oncology
• Strong expertise in rare disease trials
• Robust clinical safety system
• Choice of leading drug safety databases

Our key services include:
• Clinical Research Services
• Pharmacovigilance
• Medical Information
• Regulatory
• Medical Writing
• Site Management
• Study Physician Support
• Biostatistics
• Patient Study Support

Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this “Data-driven R&D Autobahn to Cures” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 3,700 highly qualified people. The Company’s 14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence.

At Julius Clinical, science is the foundation. Combined with flexibility, creativity, and innovation, our scientific approach enables fast, efficient, and high quality execution of complex clinical development programs. Our skilled and loyal networks of investigators all around the world allow us to offer superior recruitment in therapeutic area’s such as cardiology, diabetes, CNS and infectious diseases.

Our partners include leading pharmaceutical, biotech, medical device, and food companies, as well as academic investigators. We focus on clinical trials that are likely to have a major impact on medicine and on people’s lives. This type of demanding research requires more than a ‘one-size-fits-all’ approach, and our fusion of scientific and operational expertise enables to deliver results efficiently, on time and budget.

Julius Clinical has on its staff internationally recognised academic leaders who are actively involved in the design, conduct, and interpretation of clinical trials. This scientific expertise and credibility, combined with personal links with peers around the world, means that the company has a truly global reach and reputation. Through our global networks we can quickly select the most appropriate and high-performing sites to take part in a trial, and ensure that investigators are inspired and motivated.